Program
Bosentan
Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.
Drug pageBosentan: every studyMany companies study it; this page follows only the 30 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 260 open or running | phase 4since Apr 30, 2004 | Oct 6, 2003 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Sep 23, 2019 | Sep 23, 2019 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jun 26, 2024 | Jun 26, 2024 | none ahead |
| Retinset SLits history only | 10 open or running | phase 1since Aug 22, 2019 | Aug 22, 2019 | none ahead |
Also a collaborator on its studies: Dong-A ST.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Oct 6, 2003.
- Mar 16, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00303459 · 334 enrolled
- Apr 3, 20068 phase 3 studiesNCT00310830, NCT00313222, NCT00313196 and 5 more
- Apr 21, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00317486 · 54 enrolled
- Aug 2, 2006Phase 3 study in Hypertension, PulmonaryNCT00360087 · 236 enrolled
- Aug 21, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00367770 · 37 enrolled · United States, Australia, Austria and more
- Oct 20, 2006Phase 3 study in Idiopathic Pulmonary FibrosisNCT00391443 · 616 enrolled
- Feb 7, 2007Phase 4 study in Pulmonary Arterial HypertensionNCT00433329 · 100 enrolled
- Jan 7, 2008Phase 4 study in Hypertension, PulmonaryNCT00595049 · 11 enrolled · Australia
- Feb 12, 2008Phase 3 study in Idiopathic Pulmonary FibrosisNCT00631475 · 128 enrolled
- Oct 14, 2009Phase 2 study in MelanomaNCT01009177 · 80 enrolled · Australia
- Oct 12, 2010Phase 3 study in Pulmonary Arterial HypertensionNCT01223352 · 64 enrolled
- Apr 15, 2011Phase 3 study in Pulmonary Arterial HypertensionNCT01338415 · 58 enrolled · United States, Australia, Belarus and more
- Jun 30, 2011Phase 3 study in Persistent Fetal Circulation SyndromeNCT01389856 · 23 enrolled
- Jul 6, 2011Phase 4 study in Scleroderma, SystemicNCT01395732 · 18 enrolled · Netherlands
TargetBeta
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 14 |
Studies
All 26 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01395732Scleroderma, Systemic · Netherlands | 4 | Completed | Nov 30, 2012 | 18 |
| NCT01389856Persistent Fetal Circulation Syndrome | 3 | Terminated | Dec 2013 | 23 |
| NCT01338415Pulmonary Arterial Hypertension · United States, Australia, Belarus and more | 3 | Completed | Aug 13, 2014 | 58 |
| NCT01223352Pulmonary Arterial Hypertension | 3 | Completed | Apr 3, 2013 | 64 |
| NCT01009177Melanoma · Australia | 2 | Completed | Feb 29, 2008 | 80 |
| NCT00631475Idiopathic Pulmonary Fibrosis | 3 | Completed | Apr 2010 | 128 |
| NCT00595049Hypertension, Pulmonary · Australia | 4 | Completed | Dec 31, 2008 | 11 |
| NCT00433329Pulmonary Arterial Hypertension | 4 | Completed | May 2010 | 100 |
| NCT00391443Idiopathic Pulmonary Fibrosis | 3 | Completed | Feb 2010 | 616 |
| NCT00367770Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 4 | Completed | Dec 2005 | 37 |
| NCT00360087Hypertension, Pulmonary | 3 | Terminated | Aug 2007 | 236 |
| NCT00319696digital ulcers | 3 | Completed | Jan 22, 2009 | 116 |
| NCT00319267Pulmonary Arterial Hypertension | 3 | Completed | Dec 2006 | 36 |
| NCT00319111Hypertension, Pulmonary | 3 | Completed | Feb 2009 | 151 |
| NCT00319033Lung Diseases, Interstitial | 3 | Completed | Feb 2006 | 132 |
| NCT00319020Pulmonary Arterial Hypertension | 3 | Completed | Oct 28, 2011 | 33 |
| NCT00317486Pulmonary Arterial Hypertension | 4 | Completed | Apr 2005 | 54 |
| NCT00313222Chronic Thromboembolic Pulmonary Hypertension | 3 | Completed | Feb 2007 | 157 |
| NCT00313196Hypertension, Pulmonary | 3 | Terminated | Aug 2007 | 12 |
| NCT00310830Hypertension, Pulmonary | 3 | Terminated | Aug 2007 | 14 |
| NCT00303459Pulmonary Arterial Hypertension | 4 | Completed | Dec 2013 | 334 |
| NCT00091715Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Completed | Nov 2006 | 185 |
| NCT00082186Hypertension, Pulmonary | 4 | Completed | Feb 2007 | 22 |
| NCT00077584digital ulcers | 3 | Completed | Mar 2005 | 188 |
| NCT00071461Idiopathic Pulmonary Fibrosis · United States, Canada, France and more | 3 | Completed | Sep 2005 | 158 |
| NCT00070590Pulmonary Fibrosis | 3 | Completed | Sep 2005 | 132 |
How it is read
Names in the registry
- “Bosentan”, 19 entries
- “bosentan”, 12 entries
- “Bosentan 125 mg”, 3 entries
- “Bosentan 62.5 mg”, 2 entries
- “Bosentan Dispersible Tablets”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 14 studies
- Hypertension, Pulmonary, 6 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- digital ulcers, 2 studies
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.